PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 5, 2026Biomaterials Science2 citations

tPLGA nanoparticles combined with CCL2/CCR2 inhibitor mitigate post-thrombolytic hemorrhagic transformation

View Full Paper
FLFeiyang LuoJPJingmei PanZWZhenhua Wang

Key Points

  • This research aims to examine the effect of tPLGA nanoparticles and CCL2/CCR2 inhibition on preventing hemorrhagic transformation after thrombolysis.
  • Utilized an MMP-9-responsive tPLGA nanoplatform for targeted delivery of tPA.
  • Incorporated CCL2/CCR2 inhibitors to assess changes in neuroinflammation.
  • Evaluated the preservation of blood-brain barrier (BBB) integrity post-treatment.
  • CCL2/CCR2 inhibition significantly reduced neuroinflammation following treatment.
  • tPLGA nanoparticles effectively facilitated targeted thrombolysis without increasing hemorrhagic transformation rates.
  • Preservation of BBB integrity was observed, indicating improved safety profiles.

Abstract

An MMP-9-responsive tPLGA nanoplatform enables spatiotemporally controlled tPA delivery for targeted thrombolysis. Coupling with CCL2/CCR2 inhibition suppresses neuroinflammation, preserves BBB integrity, and prevents hemorrhagic transformation.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Luo et al. (2026) studied this question.

synapsesocial.com/papers/698435e5f1d9ada3c1fb5380https://doi.org/10.1039/d5bm01807b
Ask AI
Helpful
Bookmark
Share
View Full Paper